Investigational drug · Phase 3
Alimatravir
Also called: MK-8527
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis, HIV.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
1
Any phase or sponsor naming "Alimatravir"
First trial start
2023
Nov 8, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Alimatravir", any sponsor or status.
Conditions studied
As listed on its trial records.
- Human Immunodeficiency Virus (HIV)
- HIV Pre-Exposure Prophylaxis
- HIV
- HIV Pre-exposure Prophylaxis
Approved drugs for the same conditions: Infectious disease and vaccines · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Alimatravir" as an intervention, largest first.
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07850609 · 80 participants (planned) · Start Oct 27, 2026 · Primary completion Dec 2, 2027
Drug: Alimatravir · For: HIV
Sites: San Francisco, California; Washington D.C., District of Columbia; Boston, Massachusetts · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Alimatravir Oral Once Monthly in Adults With Low Likelihood of HIV Exposure: A Randomized, Double-Blind, Placebo-Controlled Study.
Mayer KH, Kotze P, Lombaard J, et al. · J Infect Dis 2026
- Stereoselective Synthesis of MK-8527 Enabled by a Dynamic Kinetic Resolution Mitsunobu Glycosylation.
Whittaker AM, Peng F, Sirota E, et al. · Org Lett 2026
- Merck's alimatravir licensing deal receives mixed response.
Holt E · Lancet Infect Dis 2026
- The estimated cost of MK-8527 produced at scale for once-monthly oral HIV pre-exposure prophylaxis in low- and middle-income countries.
Cross S, Levi J, Venter F, et al. · AIDS 2026
- Targeted universalism for long-acting PrEP: an urgent need to avoid risk targeting and build population-level impact.
Beres LK, Schwartz SR, Olum R, et al. · Lancet HIV 2026
- Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies.
Carstens RP, Kapoor Y, Vargo RC, et al. · Clin Infect Dis 2026
Also in development for Human Immunodeficiency Virus (HIV)
- TDFPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis, Chronic Hepatitis B Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.